Vorinostat as a Potential Therapy for Gastric Cancer
Author Information
Author(s): Claerhout Sofie, Lim Jae Yun, Choi Woonyoung, Park Yun-Yong, Kim KyoungHyun, Kim Sang-Bae, Lee Ju-Seog, Mills Gordon B., Cho Jae Yong
Primary Institution: The University of Texas MD Anderson Cancer Center
Hypothesis
Can gene expression signature analysis identify effective therapeutic agents for gastric cancer?
Conclusion
Vorinostat has been identified as a potential therapeutic agent for gastric cancer, showing efficacy in inducing apoptosis and autophagy in cancer cell lines.
Supporting Evidence
- Vorinostat induced apoptosis and autophagy in gastric cancer cell lines.
- Gene expression analysis identified specific genes that were downregulated by vorinostat treatment.
- Connectivity Map analysis confirmed vorinostat as a top candidate for gastric cancer therapy.
Takeaway
Researchers found that a drug called vorinostat might help treat stomach cancer by making cancer cells die. They used special tests to see how it worked.
Methodology
The study used microarray technology to analyze gene expression profiles from gastric cancer tissue samples and performed Connectivity Map analysis to identify candidate drugs.
Potential Biases
Potential bias in drug efficacy due to the limited number of cell lines used in the study.
Limitations
The study's findings may not fully translate to in vivo conditions due to the complexity of human cancer and the limitations of cell line data.
Participant Demographics
The study included 65 gastric cancer patients, predominantly male (71%) with a median age of 63 years.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website